If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

JCC Subsidiary Agreement

1 Jun 2006 07:01

Marchpole Holdings PLC01 June 2006 Marchpole Holdings plc ("Marchpole" or "the Group") Subsidiary Jean Charles de Castelbajac Shop in shop agreement with Galleries Lafayette Marchpole Holdings plc, the fast growing fashion brand management group, ispleased to announce that its wholly owned subsidiary Jean Charles de Castelbajac("JCC") has signed a contract with Galleries Lafayette to open a 'shop-in-shop'in the landmark Galleries Lafayette department store on Boulevard Hausman inParis. The agreement will see clothes and accessories from the JCC range being sold in350 sq feet of store space in the iconic Parisian store from July 2006. Thisagreement follows JCC's major new licence agreement with OKAIDI Group, announcedin May 2006, and is another significant step in the development of the brand,following Marchpole's acquisition of JCC in 2004. In addition to enhancing thereputation of the JCC brand, the opening will broaden the reach of the brand andincrease the turnover of JCC. Group Galleries Lafayette, one of France's largest retailers, has 61 "GalleriesLafayette" stores throughout France. In 2005, the Group made over €4,943.6million in sales. The Group's flagship Boulevard Hausman department storehouses a wide range of international luxury brands. Michael Morris, executive Deputy Chairman of Marchpole, commented: "I'mdelighted with this latest development for Jean Charles de Castelbajac whichwill increase the brand's presence and reputation in a key target market. Theagreement underlines Marchpole's commitment to growing our business andextending the reach of our brands." - ends - For further information: Emma Kent, Bell Pottinger Corporate & Financial: 0207 861 3232 John Harrison, Finance Director, Marchpole: 0207 908 7777 Notes to Editors - Marchpole Holdings plc ("Marchpole") is an international brand management group that designs, produces and sells clothing and accessories for seven world class fashion labels. It operates in all of the world's main markets - UK, mainland Europe, Asia and the USA - Its respected brands include YSL, Boateng, Emmanuel Ungaro, Ungaro, Jean-Charles de Castelbajac ("JCC"), Jean-Charles de Castelbajac / Rossignol and Jean-Charles de Castelbajac / Okaidi - Incorporated in 1973, Marchpole listed on the London Stock Exchange in 1997 and has the ticker symbol MPH - Marchpole is renowned for its integrated approach to brand management, taking a brand from concept to design studio to the customer interface. It is not a clothing manufacturer - The Group has grown considerably in the past 3 years, from a licensee with one core license (YSL menswear) - to today's international business that manages its brands across a multitude of clothing lines and accessories - Marchpole's most recent acquisition (March 2006) of Moda America - the US licensee for leading designer Emanuel Ungaro - brings further growth opportunities in the UK and America and strengthens the company's relationship with Ungaro - The acquisition also allows the company to launch the Ungaro brand, already established by Marchpole in Europe and Asia, into the US, Canada and South America. The acquisition also allows the company to re-launch JCC into America with effect from autumn/winter 2006 - Marchpole will launch the diffusion Ungaro Homme collection in the UK from Spring/Summer 2007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.